Shares of Apollo Hospitals Enterprise Ltd. jumped approximately 4% intraday, trading near ₹7,555 on the BSE, following the board’s approval to demerge and separately list its omni‑channel pharmacy and digital health business. The stock’s strong start highlighted investor enthusiasm for the transformational move.

What the Board Approved

  • A composite scheme of arrangement will spin off Apollo’s digital health, telehealth, and pharmacy ventures—including Apollo HealthCo (AHL), Keimed, and Apollo Medicals—into a new entity (“NewCo”).
  • The company aims to list NewCo within 18–21 months, while retaining a 15% stake in the new entity to maintain integrated ecosystem synergy.

Strategic and Market Rationale

  1. Value unlocking through focused listing
    Analysts believe the move will reduce corporate complexity and unlock value by separating fast-growing pharmacy and digital operations from the core hospital business.
  2. Healthy revenue targets
    NewCo targets ₹25,000 crore in revenue by FY27 with 7% EBITDA margin—a scale comparable to leading standalone healthcare platforms.
  3. Strong institutional backing
    Leading research firms, including Morgan Stanley and Citi, have reaffirmed Buy ratings on Apollo, projecting significant upside to ₹8,058–₹8,260, citing streamlined structure and value appreciation for shareholders.
  4. Phase-wise strategic demerger
    The demerger process includes merging existing pharmacy subsidiaries and digital platforms into NewCo, ensuring clean ownership and regulatory compliance ahead of public listing.

Market Reaction & Technical Momentum

  • Stock performance: Rallied 4% intraday, breaking past recent resistance around ₹7,400. The upmove coincided with renewed long-only interest and short covering.
  • Volume surge: Trading volumes swelled, with mixed retail and institutional participation signaling sustained confidence.

Conclusion

Apollo Hospitals’ strategic move to spin off its pharmacy and digital health businesses reflects a deliberate push toward unlocking value and simplifying its corporate structure. With a high-growth entity set to be listed and strong brokerage support, the parent company’s stock is gaining momentum. The next 18–21 months will be pivotal—watch for execution on NewCo listing plans, regulatory milestones, and sector performance to sustain investor optimism.

Disclaimer: This article is for informational purposes only and does not constitute financial, investment, or legal advice. Stock market investments involve risks. Readers should conduct independent research or consult a SEBI-registered advisor before making investment decisions.

Also Read: Kalpataru Share Price Extends Gains Over 4% After Flat IPO Listing

Post Views: 82